90
Participants
Start Date
November 1, 2020
Primary Completion Date
October 31, 2022
Study Completion Date
April 30, 2023
Trifluridine/Tipiracil
TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days
Bevacizumab
Bevacizumab 5 mg /kg, intravenously on days 1,15,every 28 days
Hunan Cancer hospital, Changsha
Hunan Cancer Hospital
OTHER